Walgreens collects more than 15,000 lbs. of unused, expired medications
HOUSTON — Walgreens’ Safe Medication Disposal Program, launched in September 2010 in partnership with Sharps Compliance, has collected more than 15,000 lbs. of unused or expired medications, Walgreens announced Monday.
“We estimate that more than 200 million lbs. of unused dispensed medications are disposed of improperly each year,” Sharps Compliance president and CEO David Tusa said.
“We are encouraged that many of our patients have taken advantage of this medication disposal opportunity,” stated Richard Ashworth, Walgreens VP pharmacy operations. “In addition to the environmental benefits, it addresses a common safety concern in communities. Customers are pleased to have a solution that allows them to be environmentally responsible and keep medications out of unintended hands with convenience and ease.”
As part of the program, U.S. Postal Service-approved envelopes are available at Walgreens for $3.99 for customers to place, seal and mail prescription or over-the-counter medications they no longer use to a facility for proper treatment. Controlled substances are excluded from this program due to current regulations. Postage is included in the cost of the envelope.
Pozen, AstraZeneca file suit against Dr. Reddy’s over generic Vimovo
CHAPEL HILL, N.C. — A generic drug maker is being sued for patent infringement for its version of a fixed-dose combination drug co-created by Pozen and AstraZeneca.
Pozen and AstraZeneca on Monday said that they have filed the suit in the U.S. District Court for the District of New Jersey against Dr. Reddy’s. The drug makers said Dr. Reddy’s is seeking approval from the Food and Drug Administration for its generic version of Vimovo (naproxen/esomeprazole magnesium) delayed-release tablets prior to the patent’s expiration date. Vimovo currently has regulatory exclusivity through April 30, 2013, Pozen and AstraZeneca said.
The filing of this patent infringement lawsuit by AstraZeneca and Pozen within 45 days of receipt of Dr. Reddy’s notice letter will result in the FDA automatically instituting a stay or bar of final approval of Dr. Reddy’s abbreviated new drug application for up to 30 months, or until a final court decision is entered in the infringement suit in favor of Dr. Reddy’s, whichever occurs first.
Marc’s aims for low prices
Cleveland, Ohio-based Marc’s will sell almost anything, provided it can price the item low and turn it quickly. But it won’t sell shrunken heads.
“We went to one customs auction a while ago and bought some artifacts,” said company founder Marc Glassman in a recent YouTube video. “Then we found out we’d bought some real shrunken heads from Peru. We were quite embarrassed.”
Heads aside, Glassman’s eccentric, eclectic retail brainchild is thriving — in part by defying retail norms. In an era of just-in-time logistics, the 60-store Marc’s chain — Glassman also owns five-store Xpect in Connecticut — doesn’t hesitate to buy multi-truckload quantities of deal and closeout merchandise to lock in a low price.
“With 60 stores, we have well over 1 million sq. ft. of warehouse, just to … bring stuff in,” Glassman said. “Some stuff we bring in six to eight months before the season, but if you’re buying closeouts — especially seasonal closeouts — you have to buy when it’s there.”
“We just want to turn products fast at the lowest prices,” Glassman said. “Literally no one in the country marks closeouts as low as we do.”
The discounts extend to the chain’s more than 50 pharmacies, with a $3.99 price point on more than 400 generic drugs and everyday low prices on diabetic supplies, blood-pressure monitors, digital thermometers, reading glasses, dietary supplements and more.